ArticleFrontiers in chemistry2026
Integrative characterization of Huachansu against hepatocellular carcinoma: chemical profiling, Network pharmacology, and
Article in Frontiers in chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) remains a major global health burden, and traditional Chinese medicine (TCM) offers complementary therapeutic advantages. Although Huachansu (HCS), a clinically used TCM preparation, contains key bioactive components, including bufalin (BFL) and cinobufotalin (CBF), its antitumor mechanisms remain unclear. Methods: LC-MS profiling was performed to characterize the chemical constituents of HCS. Network pharmacology analysis was conducted by integrating predicted compound targets with HCC-associated genes to identify overlapping targets and enriched biological pathways. Subsequently, molecular docking was used to evaluate binding interactions between active compounds and hub proteins. Finally, the antitumor effects of BFL and CBF were validated Results: LC-MS profiling identified 17 HCS constituents, predominantly bufadienolides, establishing a chemical basis for mechanistic analyses. Network pharmacology analysis defined 142 overlapping targets enriched in apoptosis-related processes and cancer pathways. Molecular docking supported stable binding between bioactive compounds and key hub proteins, including STAT3, EGFR, AKT1, and PARP1, suggesting apoptosis-centered regulation. Guided by these Conclusion: These findings clarify the apoptosis-associated anti-HCC mechanism of HCS and provide mechanistic insights supporting development of TCM-based anticancer agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.